查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1879237

增生療法市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、地區和競爭格局分類，2020-2030年預測

Prolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球增生療法市場規模為12.8041億美元，預計到2030年將以6.90%的複合年成長率成長至19.108億美元。增生療法，又稱增殖療法，是一種注射式再生醫學治療方法，旨在透過在韌帶和肌腱薄弱部位誘導可控的發炎反應來刺激人體自身的癒合過程。此療法通常使用高滲透壓葡萄糖溶液來促進組織再生並強化結締組織。全球增生療法市場的成長主要受以下因素驅動：全球慢性肌肉骨骼疾病盛行率的不斷上升，以及對非手術、微創疼痛管理治療方案日益成長的需求。

市場概覽
預測期 2026-2030
2024年市場規模 12.8041億美元
2030年市場規模 19.108億美元
2025-2030年複合年成長率 6.9%
成長最快的細分市場 醫院
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球增生療法市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（關節注射增生療法、韌帶增生療法、肌腱重建增生療法）
    • 依應用領域（醫院、門診中心、骨科中心、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美增生療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲增生療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區增生療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲增生療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲增生療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球增生療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Pfizer Inc.
  • Baxter International Inc.
  • B. Braun AG
  • Fresenius SE & Co. KGaA
  • ICU Medical, Inc.
  • Johnson & Johnson
  • Arthex Inc.
  • Aurobindo Pharma Limited
  • Terumo Corporation
  • Amphastar Pharmaceuticals, Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 15750

The Global Prolotherapy Market, valued at USD 1280.41 Million in 2024, is projected to experience a CAGR of 6.90% to reach USD 1910.80 Million by 2030. Prolotherapy, or proliferative therapy, is an injection-based regenerative medical treatment designed to stimulate the body's natural healing processes by inducing a controlled inflammatory response at the site of weakened ligaments and tendons, typically utilizing hyperosmolar dextrose solutions to foster tissue regeneration and strengthen connective tissues. The global prolotherapy market's expansion is fundamentally driven by the escalating prevalence of chronic musculoskeletal disorders worldwide and the growing demand for non-surgical, minimally invasive treatment alternatives for pain management.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1280.41 Million
Market Size 2030USD 1910.80 Million
CAGR 2025-20306.9%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

The escalating global prevalence of musculoskeletal disorders and chronic pain represents a primary market driver for prolotherapy. These conditions significantly impact quality of life and impose substantial healthcare burdens worldwide. The widespread nature of these ailments creates a consistently large patient pool seeking effective and less invasive treatment options. According to the International Association for the Study of Pain, in July 2023, "Global Burden of Musculoskeletal Conditions", an estimated 1.71 billion people globally were in need of rehabilitation due to musculoskeletal conditions, highlighting the extensive demand for therapies addressing such widespread issues. As incidence rates continue to rise, the foundational need for treatments like prolotherapy becomes increasingly pronounced, directly stimulating market expansion by providing solutions for persistent pain and functional limitations.

Key Market Challenges

The limited availability of robust, high-quality clinical evidence poses a significant impediment to the expansion of the global prolotherapy market. This evidentiary gap directly impacts the confidence of healthcare providers in recommending prolotherapy as a primary treatment option. Without comprehensive, long-term studies demonstrating consistent efficacy and safety, medical professionals often hesitate to integrate such interventions into standard practice protocols, thereby constraining patient referrals and limiting overall adoption rates.

Furthermore, the absence of strong clinical evidence fuels persistent regulatory uncertainty and contributes to variable insurance reimbursement policies across regions. For instance, according to the American Society of Interventional Pain Physicians (ASIPP) 2024 guidelines, the evidence for intradiscal injections of Platelet-Rich Plasma (PRP) and Mesenchymal Stem Cells (MSCs) is categorized as Level III, and Level IV for other related joint injections, on a five-level scale where Level I represents the strongest evidence. This limited strength of evidence for related regenerative therapies leads insurers to hesitate in covering treatments lacking substantial proof of long-term effectiveness. Such financial barriers reduce patient access, thereby stifling market penetration and growth.

Key Market Trends

Two key trends are significantly shaping the global prolotherapy market. Technological enhancements in injection guidance are improving the precision and safety of prolotherapy procedures, thereby increasing both practitioner confidence and patient acceptance. The integration of advanced imaging modalities, such as ultrasound, provides real-time visualization during injections, allowing for more accurate targeting of damaged tissues and minimizing potential complications. According to the Society of Diagnostic Medical Sonography, March 2024, "Now Available: Revised Scope of Practice and Clinical Standards for the Diagnostic Medical Sonographer," twenty participating organizations collaborated to revise the Scope of Practice and Clinical Standards for Diagnostic Medical Sonographers, reflecting the rapid technological advancements and evolving role of sonography in interventional procedures. This emphasis on enhanced guidance supports the widespread adoption of more accurate delivery methods for regenerative treatments.

Key Market Players

  • Pfizer Inc.
  • Baxter International Inc.
  • B. Braun AG
  • Fresenius SE & Co. KGaA
  • ICU Medical, Inc.
  • Johnson & Johnson
  • Arthex Inc.
  • Aurobindo Pharma Limited
  • Terumo Corporation
  • Amphastar Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Prolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prolotherapy Market, By Type:

  • Joint Injection Prolotherapy
  • Ligament Prolotherapy
  • Tendon Reconstruction Prolotherapy

Prolotherapy Market, By Application:

  • Hospitals
  • Ambulatory Care Centers
  • Orthopedic Centers
  • Others

Prolotherapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prolotherapy Market.

Available Customizations:

Global Prolotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prolotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Joint Injection Prolotherapy, Ligament Prolotherapy, Tendon Reconstruction Prolotherapy)
    • 5.2.2. By Application (Hospitals, Ambulatory Care Centers, Orthopedic Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Prolotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prolotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Prolotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Prolotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Prolotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Prolotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Prolotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Prolotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Prolotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Prolotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Prolotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Prolotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Prolotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Prolotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Prolotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Prolotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Prolotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Prolotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Prolotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Prolotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Prolotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Prolotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Prolotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Prolotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Prolotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter International Inc.
  • 15.3. B. Braun AG
  • 15.4. Fresenius SE & Co. KGaA
  • 15.5. ICU Medical, Inc.
  • 15.6. Johnson & Johnson
  • 15.7. Arthex Inc.
  • 15.8. Aurobindo Pharma Limited
  • 15.9. Terumo Corporation
  • 15.10. Amphastar Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer